Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells 7,250 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh Bhatt sold 7,250 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total transaction of $359,600.00. Following the transaction, the vice president directly owned 17,044 shares in the company, valued at approximately $845,382.40. The trade was a 29.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded down $1.53 during mid-day trading on Wednesday, reaching $49.29. 575,953 shares of the company were exchanged, compared to its average volume of 757,563. The firm has a market cap of $2.84 billion, a P/E ratio of -72.48, a PEG ratio of 1.56 and a beta of 0.70. The business has a fifty day moving average of $51.26 and a 200 day moving average of $49.17. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $59.68.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on SUPN shares. Stifel Nicolaus raised their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $62.17.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. raised its holdings in shares of Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the last quarter. Rockefeller Capital Management L.P. increased its position in shares of Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares during the period. Torren Management LLC purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth $49,000. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals during the 3rd quarter worth about $50,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at about $51,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.